Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsCharacteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.A randomized controlled trial of a diagnostic algorithm for symptoms of uncomplicated cystitis at an out-of-hours service.High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.Escherichia coli sequence type 131: epidemiology and challenges in treatment.Treatment of drug-resistant Shigella infections.The emerging threat of multidrug-resistant Gram-negative bacteria in urology.Role of old antimicrobial agents in the management of urinary tract infection.A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.Introduction of a Simple Second Tier Screening Test for C5 Isobars in Dried Blood Spots: Reducing the False Positive Rate for Isovaleric Acidaemia in Expanded Newborn Screening.Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review.
P2860
Q21131083-D5C1901E-5F19-4492-9716-AEC4BEA976CBQ36180580-B3EE55D4-26EC-4506-8AB0-2DD0B3562BF6Q36209009-D4C516C7-48A7-444E-8499-9D74AC64AB68Q36806280-237952E6-9C5E-42D5-B27F-D7472B5E7DF1Q37484304-3BAE787F-3FD6-4C3F-8E28-17563FF833EFQ38201515-466E93C3-3CD3-4193-B775-8BB89D2F8932Q38268512-7F3C948D-9A25-4036-B5C1-D50C3F7A245CQ38579512-FEF54025-660F-4AF9-97CA-F0A670C227E6Q38832723-CBA1E69A-31C3-4B2E-AC38-C6377D7853FAQ40267528-F5F88F02-3F37-4C81-8F49-85DFA29D1ED4Q40967518-01D1902E-DA98-413E-9EF1-79DC96F244E1Q54943112-1C0CB647-6C21-45C2-88DA-B8644EC11356Q55113256-F6C4EBED-A75C-4DF1-BEE8-B2EBD32387BA
P2860
Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging clinical role of pivm ...... multidrug-resistant bacteria.
@en
type
label
Emerging clinical role of pivm ...... multidrug-resistant bacteria.
@en
prefLabel
Emerging clinical role of pivm ...... multidrug-resistant bacteria.
@en
P2093
P2860
P356
P1476
Emerging clinical role of pivm ...... multidrug-resistant bacteria.
@en
P2093
Lee C Reed
Roland J Koerner
Simon Dewar
P2860
P304
P356
10.1093/JAC/DKT368
P407
P577
2013-09-25T00:00:00Z